The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Management and outcomes for primary cardiac sarcomas (PCS): A retrospective study of the French Sarcoma Group (FSG).
N. Isambert
Consultant or Advisory Role - PharmaMar
I. L. Ray-Coquard
Consultant or Advisory Role - Novartis; PharmaMar; Roche
Honoraria - Novartis; PharmaMar; Roche
Research Funding - Merck
B. Bui Nguyen
Consultant or Advisory Role - Novartis; PharmaMar
M. Rios
No relevant relationships to disclose
P. Kerbrat
No relevant relationships to disclose
A. Blouet
No relevant relationships to disclose
L. Chaigneau
No relevant relationships to disclose
F. Duffaud
No relevant relationships to disclose
S. Piperno-Neumann
No relevant relationships to disclose
J. Kurtz
No relevant relationships to disclose
J. Thariat
No relevant relationships to disclose
N. Girard
No relevant relationships to disclose
O. Collard
No relevant relationships to disclose
E. Bompas
No relevant relationships to disclose
N. Penel
No relevant relationships to disclose
J. Bay
No relevant relationships to disclose
C. Guillemet
No relevant relationships to disclose
F. Collin
No relevant relationships to disclose
J. Blay
Consultant or Advisory Role - GlaxoSmithKline; ImClone Systems; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
A. Le Cesne
Consultant or Advisory Role - Novartis; Pfizer; PharmaMar
Honoraria - Novartis; Pfizer; PharmaMar